Evidence map›Paper›PMID 37130851›Full record

ArticleNature communications2023

Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery.

Henry T Hsueh, Renee Ti Chou, Usha Rai, Wathsala Liyanage, Yoo Chun Kim, Matthew B Appell, Jahnavi Pejavar, Kirby T Leo, Charlotte Davison, Patricia Kolodziejski and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Machine Learning-Enhanced Nanoparticle Design for Precision Cancer Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Learning what keeps nanomedicines in tumours.Nature biomedical engineering · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Henry T Hsueh *Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Renee Ti Chou *Center for Bioinformatics and Computational Biology, University of Maryland, College Park, College Park, MD, USA.ORCID 0000-0002-8755-6938
Usha RaiCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wathsala LiyanageCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yoo Chun KimCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthew B AppellCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jahnavi PejavarCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kirby T LeoCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1717-5862
Charlotte DavisonCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Patricia KolodziejskiCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ann MozzerCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
HyeYoung KwonCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-6928-7279
Maanasa SistaCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-3360-5634
Nicole M AndersThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Avelina HemingwayThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA.
Sri Vishnu Kiran RompicharlaCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Malia EdwardsDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ian PithaCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2670-9117
Justin HanesCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9672-9821
Michael P CummingsCenter for Bioinformatics and Computational Biology, University of Maryland, College Park, College Park, MD, USA. mcummin1@umd.edu.ORCID 0000-0002-1467-0334
Laura M EnsignCenter for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. lensign@jhmi.edu.ORCID 0000-0002-6949-7911
Johns Hopkins University · USUniversity of Maryland, College Park · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Visual Science Training ProgramT32EY007143 · NEI · JOHNS HOPKINS UNIVERSITY · PI Laura Ensign, JEREMY NATHANS · 1995 to 2026
$6.2M
Sustained-release of novel neuroprotective agents for treatment of glaucomaR01EY026578 · NEI · JOHNS HOPKINS UNIVERSITY · PI ENSIGN, LAURA · 2016 to 2020
$2.0M
A novel hypotonic gelling eye drop for topical treatment of retinal degenerative diseasesR01EY031041 · NEI · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, ENSIGN, LAURA · 2020 to 2023
$1.6M
Acquisition of a triple quadrupole mass spectrometer for small molecule analysisS10OD020091 · OD · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2015 to 2015
$314k
NCATS NIH HHS UL1 TR001079NCI NIH HHS P30 CA006973NEI NIH HHS R01 EY026578NEI NIH HHS R01 EY031041NEI NIH HHS T32 EY007143NIH HHS S10 OD020091U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01EY026578U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01EY031041
6 · The paper itself

Abstract

Sustained drug delivery strategies have many potential benefits for treating a range of diseases, particularly chronic diseases that require treatment for years. For many chronic ocular diseases, patient adherence to eye drop dosing regimens and the need for frequent intraocular injections are significant barriers to effective disease management. Here, we utilize peptide engineering to impart melanin binding properties to peptide-drug conjugates to act as a sustained-release depot in the eye. We develop a super learning-based methodology to engineer multifunctional peptides that efficiently enter cells, bind to melanin, and have low cytotoxicity. When the lead multifunctional peptide (HR97) is conjugated to brimonidine, an intraocular pressure lowering drug that is prescribed for three times per day topical dosing, intraocular pressure reduction is observed for up to 18 days after a single intracameral injection in rabbits. Further, the cumulative intraocular pressure lowering effect increases ~17-fold compared to free brimonidine injection. Engineered multifunctional peptide-drug conjugates are a promising approach for providing sustained therapeutic delivery in the eye and beyond.

Indexed as

Drug Delivery SystemsMelaninsAnimalsBrimonidine TartrateMachine LearningPeptidesRabbitsBrimonidine TartrateMelaninsPeptides

Identifiers

PMID37130851
PMCPMC10154330
OpenAlexW4367692695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.